{"id":"W3091625009","doi":"10.1158/1078-0432.ccr-20-1068","title":"Phase Ib Dose-escalation/Expansion Trial of Ribociclib in Combination With Everolimus and Exemestane in Postmenopausal Women with HR+, HER2− Advanced Breast Cancer","year":2020,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"ca_institutions":"Institute of Cancer Research","funders":"National Cancer Institute; Novartis","keywords":"Exemestane; Everolimus; Postmenopausal women; Clinical trial; Breast cancer; Phases of clinical research; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001184881,0.0008689546,0.001598001,0.0003263129,0.0003533394,0.0005424762,0.0007080451,0.0007906333,0.001863205],"category_scores_gemma":[0.0006509089,0.0004344468,0.0006397109,0.000373731,0.0004953291,0.0005311721,0.0002949251,0.002805432,0.0004376752],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006746864,"about_ca_system_score_gemma":0.0009561746,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006954863,"about_ca_topic_score_gemma":0.002099426,"domain_scores_codex":[0.9996275,0.0001652972,0.00002991201,0.000059004,0.00005317828,0.00006515998],"domain_scores_gemma":[0.9995671,0.0000613933,0.0001058258,0.00005746701,0.00002750107,0.0001807501],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5457235,0.1079463,0.01052202,0.0006317948,0.001417278,0.0003521896,0.0005102689,0.003942502,0.1737872,0.0002323091,0.003392794,0.1515419],"study_design_scores_gemma":[0.357056,0.590911,0.02527025,0.0000428131,0.0006137721,0.0006011687,0.00008701903,0.002166885,0.01978475,0.0001665639,0.003260931,0.00003878993],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9975634,0.0006459486,0.000219749,0.0001210459,0.00002977178,0.0006876769,0.0001724756,0.00003708166,0.0005229694],"genre_scores_gemma":[0.9953126,0.0005334893,0.001213756,0.0003064013,0.00006087333,0.0009466493,0.0006503341,0.00001323168,0.0009625583],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001863205,"threshold_uncertainty_score":0.006266296,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1001927065520941,"score_gpt":0.4821527075478383,"score_spread":0.3819600009957443,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}